CIA
CTIC

Capital Impact Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Capital Impact Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5,420
Closed -$128K – 354
2014
Q4 		$128K Buy
5,420
+5,415
+108,300% +$125K 0.06% 189
2014
Q3 		$131 Sell
5
-2,705
-100% -$70.3K ﹤0.01% 181
2014
Q2 		$76K Buy
+2,710
New +$81.4K 0.06% 218

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

Capital Impact Advisors's CTIC Position: Q1 2015 in Review

Capital Impact Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2015, closing a stake of 5,420 shares — an estimated $128K sold.

Capital Impact Advisors first reported a position in CTIC in Q2 2014 and held it in 3 quarters. The position peaked at $128K in Q4 2014. 98 funds tracked by Wall St. Rank hold CTIC as of Q1 2015.

  • Capital Impact Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2015 after selling out during the quarter.
  • Capital Impact Advisors sold 5,420 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2015, an estimated $128K.
  • Capital Impact Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2014 and held it in 3 quarters.
  • Capital Impact Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $128K in Q4 2014.
  • 98 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2015.

Based on Capital Impact Advisors's 13F filing for Q1 2015, filed 29 May 2015.